Magazine Article | March 1, 2019

Companies To Watch: Azitra

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome. The products are in three categories: consumer products containing proprietary microbe strains, pharmaceuticals using microbes to produce and deliver therapeutic proteins to the skin, and “novel bioactive compounds” derived by genetic engineering of commensal microbes. At this point, the company has a pipeline of four candidates, almost all still at the discovery or preclinical stages, for treating a range of skin conditions: eczema and ichthyosis vulgaris, Netherton syndrome, inflammatory disease in psoriasis, rashes associated with cancer treatment, and cosmetic use (rough, dry skin). The first cosmetic clinical study began in January 2019.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: